- Datum15.01.2025
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Thomas May
Moderator
Formycon AG Aktie
Verkaufen
Kaufen
Formycon AG Chart
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Formycon AG Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (XETRA)
0,95 %
Intraday
1,14 %
1 Woche
6,31 %
1 Monat
-5,85 %
Seit Jahresbeginn
-5,85 %
1 Jahr
-10,00 %
3 Jahre
66,46 %
5 Jahre
401,65 %
10 Jahre
Wikifolio
Passender Service zu Formycon AG
Webinar zu Formycon AG
Kursinformationen (XETRA)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)37,650-57,000
- Jahrestief / Hoch (€)37,650-57,000
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Formycon AG
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| - | 2025 (e) |
Termine von Formycon AG
- Apr24Formycon AGQ4 2024 Earnings Release
- Jun18Formycon AGHauptversammlung
- Jun25Formycon AGQ1 2025 Earnings Release
Beschreibung
Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
